Target intelligence / Profile preview

Tear Film Stabilization Pathway

Molecular classification
Other
01

Overview

The tear film stabilization pathway refers to the complex biological processes that maintain the integrity and function of the tear film covering the ocular surface. The tear film consists primarily of three layers: an outer lipid layer produced by meibomian glands that reduces evaporation and provides stability through interaction with underlying aqueous-mucin phases, an aqueous layer secreted by lacrimal glands containing water-soluble proteins like lysozyme and immunoglobulins for antimicrobial defense, and an inner mucin layer anchored to epithelial cells that ensures even spreading over the cornea. Membrane-associated mucins are critical for anchoring this structure to epithelial microplicae while soluble mucins facilitate movement across glycocalyx surfaces due to repulsive forces between them. The coordinated action among these layers—lipid barrier formation against evaporation, aqueous secretion providing nutrients/antimicrobials/immunoglobulins/sIgA via conjunctival plasma cells—and regulated shedding/renewal mechanisms ensure continuous protection from desiccation/infection while maintaining optical clarity essential for vision quality. Disruption leads directly toward dry eye syndrome characterized by discomfort/inflammation/increased risk infection due loss barrier function reduced lubrication capacity impaired wound healing responses at corneal level.

Other names
Ocular surface homeostasis pathwayTear film maintenance mechanismLacrimal functional unit pathway
02

Mechanism of action

Lubrication and hydration of ocular surface; Modulation of inflammatory pathways on the ocular surface; Enhancement of endogenous tear production or stability

03

Biological functions

Maintenance of ocular surface hydrationBarrier function against pathogensProtection from desiccation and foreign particlesOptical clarity of cornea
04

Disease associations

Dry eye diseaseOcular surface inflammationInfection susceptibility
05

Safety considerations

Local irritation with topical agentsRisk of infection with immunosuppressive agents if used long-term
06

Interacting drugs

Artificial tears (e.g., carboxymethylcellulose)

3 more in the full profile.

07

Biomarkers

Tear breakup time (TBUT)Schirmer test score for tear volume assessmentInflammatory markers in tears such as cytokines or matrix metalloproteinases

Beyond the preview

Go deeper on Tear Film Stabilization Pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tear Film Stabilization Pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call